Annate Bitherapeutics Technology Entered into UGA InPart Portal

Annate Bitherapeutics is proud to announce that our technology has been officially listed on the University of Georgia’s InPart portal, a digital platform designed to connect groundbreaking research and innovations with potential industry partners.

The InPart portal showcases UGA-developed technologies to foster collaboration, licensing, and translational impact. By featuring Annate’s approach to next-generation cancer therapeutics, this listing increases visibility with pharmaceutical, biotech, and investment communities actively seeking new opportunities.

This milestone represents another step forward in our mission to translate academic research into clinically meaningful therapies. We look forward to the collaborations and partnerships this exposure may generate as we continue to advance our platform.

Learn more on the UGA InPart portal:
Annate Bitherapeutics on UGA InPart